UK Healthcare, University of Kentucky College of Pharmacy, 800 Rose St H-110, Lexington, Kentucky 40536-0293, USA.
Antimicrob Agents Chemother. 2011 Jul;55(7):3240-3. doi: 10.1128/AAC.01680-10. Epub 2011 May 16.
The physiochemical properties of levofloxacin suggest that it is an agent which may exhibit altered pharmacokinetics in obese individuals. The purpose of this study was to describe the pharmacokinetics of a single 750-mg intravenous dose of levofloxacin in both hospitalized and ambulatory obese individuals. The hypothesis was that a standard dose of levofloxacin in obese individuals would achieve serum concentrations likely to be therapeutic. A single levofloxacin dose of 750 mg was infused over 90 min, and seven serial serum samples were subsequently obtained to evaluate the pharmacokinetics after the first dose. The peak concentrations of levofloxacin were comparable to those seen with normal-weight individuals. However, the area under the concentration-time curve and clearance were quite variable. Accelerated clearance was evident in the ambulatory obese individuals. Further investigation of the effects of obesity on the pharmacokinetics of levofloxacin is necessary to ensure optimal dosing.
左氧氟沙星的理化性质表明，它可能是一种在肥胖个体中表现出药代动力学改变的药物。本研究的目的是描述住院和门诊肥胖个体单次 750mg 静脉注射左氧氟沙星的药代动力学。假设在肥胖个体中使用标准剂量的左氧氟沙星将达到可能具有治疗作用的血清浓度。单次给予 750mg 左氧氟沙星，90 分钟内输注完毕，随后采集 7 份连续的血清样本，以评估首剂后的药代动力学。左氧氟沙星的峰浓度与正常体重个体相似。然而，浓度-时间曲线下面积和清除率差异很大。门诊肥胖个体中明显存在清除加速。需要进一步研究肥胖对左氧氟沙星药代动力学的影响，以确保最佳剂量。
